Vanda Pharmaceuticals (VNDA) had the highest return in 2009 by a US stock in the Biotechnology Industry, returning 2,281%.
| ASSET | YEAR | % RETURN |
|---|---|---|
Vanda Pharmaceuticals (VNDA) | 2009 | 2,280.95% |
Dyadic International (DYAI) | 2009 | 1,473.33% |
TG Therapeutics (TGTX) | 2009 | 837.5% |
iBio, Inc Common Stock (IBIO) | 2009 | 650% |
Achieve Life Sciences (ACHV) | 2009 | 587.65% |
EXACT Sciences (EXAS) | 2009 | 494.74% |
Gyre Therapeutics (GYRE) | 2009 | 485.43% |
GT Biopharma (GTBP) | 2009 | 427.5% |
CASI Pharmaceuticals (CASI) | 2009 | 400% |
BioCryst Pharmaceuticals (BCRX) | 2009 | 361.43% |
MediciNova (MNOV) | 2009 | 348.41% |
Alaunos Therapeutics (TCRT) | 2009 | 341.86% |
Soligenix (SNGX) | 2009 | 316.67% |
Curis (CRIS) | 2009 | 306.25% |
Abeona Therapeutics (ABEO) | 2009 | 287.06% |
Savara (SVRA) | 2009 | 250.25% |
Protalix Biotherapeutics (PLX) | 2009 | 248.42% |
Lisata Therapeutics (LSTA) | 2009 | 244.44% |
Eterna Therapeutics (ERNA) | 2009 | 221.43% |
Galectin Therapeutics (GALT) | 2009 | 211.11% |
Theriva Biologics (TOVX) | 2009 | 211.11% |
Heron Therapeuti (HRTX) | 2009 | 207.32% |
CEL-SCI (CVM) | 2009 | 190.32% |
Evotec SE ADR (EVO) | 2009 | 185.61% |
Pluri (PLUR) | 2009 | 163.64% |
